info@seagull-health.com

SeagullHealth

语言:

Homepage

Drugs

Elacestrant(Orserdu)

Names

Orserdu,Elacestrant,艾拉司群,依拉司群

Indicatons

Advanced or metastatic breast cancer that is ER-positive, HER2-negative, and has ESR1 mutations.

Price:

Manufacturer:

Stemline

Dosage form:

TABLET

Validity period:

24 months

Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.

Orserdu(Elacestrant) Instructions:Uses,Dosage, Side Effects

ORSERDU™ (Elacestrant) is a targeted therapy designed for the treatment of ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. This medication works by inhibiting the estrogen receptor, which is a key driver of cancer cell growth. It is particularly useful for patients who have not responded well to previous endocrine therapies. The drug is available in oral tablet form and is typically administered once daily with food.

ORSERDU™ has been approved for use in postmenopausal women and adult men. However, careful monitoring is required during treatment due to potential side effects such as liver toxicity and dyslipidemia. It is essential to assess liver function regularly and to adjust doses based on the severity of side effects or drug interactions.

Generic name

Elacestrant(Orserdu)

English name

Elacestrant

Alternative Names

Orserdu,Elacestrant,艾拉司群,依拉司群

Drug prices

Indications

Treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer following disease progression after ≥1 line of endocrine therapy.

Therapeutic Target

Estrogen receptor-alpha (ERα). Elacestrant binds to ERα, induces receptor degradation via the proteasomal pathway, and inhibits estrogen-dependent tumor proliferation.

Active Ingredients

Elacestrant hydrochloride (equivalent to 345 mg or 86 mg elacestrant free base per tablet).

Dosage Form

TABLET

Specifications

345mg*30tablets/bottle

Dosage and Administration

Recommended dose: 345 mg orally once daily with food.

Related Columns

Recommended articles

Dosage and Administration, Recommended Dose of Elacestrant (Orserdu)

Elacestrant (Orserdu) is a selective estrogen receptor degrader (SERD), which provides an important treatment option for patients with estrogen receptor-positive, HER2-negative advanced or metastatic ...

What Are the Indications for Elacestrant (Orserdu)?

Elacestrant (Orserdu) is a novel endocrine therapy agent that demonstrates significant value in the treatment of advanced breast cancer with specific gene mutations. As an estrogen receptor antagonist...

What Are the Purchase Channels for Elacestrant (Orserdu)?

With the advancement of medical technology, elacestrant (Orserdu), a targeted drug for breast cancer with specific gene mutations, has brought new treatment options for patients. As the first oral sel...

What are the Precautions for Taking Elacestrant (Orserdu)?

Elacestrant (Orserdu) is the first oral selective estrogen receptor degrader (SERD). It was approved by the FDA in 2023 for the treatment of advanced or metastatic breast cancer that is estrogen recep...

Side Effects of Elacestrant (Orserdu)

Elacestrant (Orserdu) is an estrogen receptor antagonist, primarily indicated for the treatment of estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutat...

Dosage and Administration, Recommended Dose of Elacestrant (Orserdu)

Elacestrant (Orserdu) is an estrogen receptor antagonist, primarily indicated for the treatment of postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastati...

Departments